Free Trial
NASDAQ:CGON

CG Oncology Q1 2025 Earnings Report

CG Oncology logo
$26.07 +0.01 (+0.04%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$26.01 -0.06 (-0.23%)
As of 09:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CG Oncology EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.36
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

CG Oncology Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
$0.53 million
Beat/Miss
Missed by -$480.00 thousand
YoY Revenue Growth
N/A

CG Oncology Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

CG Oncology's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 8, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

CG Oncology Earnings Headlines

CGON - CG Oncology Inc Trailing Returns - Morningstar
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
CG Oncology (NASDAQ:CGON) Trading Up 4.7% After Analyst Upgrade
See More CG Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email.

About CG Oncology

CG Oncology (NASDAQ:CGON), an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

View CG Oncology Profile

More Earnings Resources from MarketBeat